A call for input has been released by NIC on Cardiovascular disease: risk assessment and reduction, including lipid modification. The call for submissions closes on Friday 22 July 2022.
- Evidence of the adverse effects of statins for primary or secondary prevention of cardiovascular disease in adults, to determine the safety of statins for lipid modification therapy. Study designs that will be included include;
- RCTs with double blinding
- Systematic reviews of RCTs
- Published network meta-analysis or individual patient data meta-analysis of RCT data.
(Abstracts, cross-over studies, non-randomised studies, and unblinded studies for subjective outcomes will not be considered.)
Please find the full information on the NICE page here.